Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to seven new employees as employment inducement awards. The options total 204,163 shares with an exercise price of $2.73 per share, matching the closing price on September 30, 2025.
The options feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia. The grants were made under Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), una società biofarmaceutica focalizzata sui trattamenti per le malattie renali, ha concesso stock option a sette nuovi dipendenti come premi di inserimento nel lavoro. Le opzioni ammontano a 204.163 azioni con un prezzo d’esercizio di 2,73 dollari per azione, pari al prezzo di chiusura del 30 settembre 2025. Le opzioni prevedono un percorso di vesting di quattro anni con il 25% che matura dopo un anno e il rimanente 75% che matura trimestralmente successivamente. Ogni opzione ha una durata di 10 anni ed è soggetta al mantenimento dell’impiego con Akebia. I premi sono stati conferiti in conformità con la Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), una empresa biofarmacéutica centrada en tratamientos para enfermedades renales, ha otorgado opciones sobre acciones a siete nuevos empleados como premios de incorporación. Las opciones totalizan 204.163 acciones con un precio de ejercicio de 2,73 dólares por acción, igualando el precio de cierre del 30 de septiembre de 2025. Las opciones tienen un régimen de vesting de cuatro años con un 25% de adquisición tras un año y el 75% restante se consolidará trimestralmente a partir de entonces. Cada opción tiene un término de 10 años y depende de la continuidad del empleo en Akebia. Los premios se concedieron conforme a la Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), 신장질환 치료에 초점을 둔 생명공학 제약회사, 고용 유인 보상으로 일곱 명의 신규 직원에게 주식매수선택권을 부여했습니다. 옵션은 총 204,163주를 보유하고 행사가는 주당 2.73달러로, 2025년 9월 30일 종가와 일치합니다. 옵션은 4년 vesting 일정을 특징으로 하며 1년 후 25%가 vesting되고 이후 분기별로 나머지 75%가 vesting됩니다. 각 옵션의 만료기간은 10년이며 Akebia에서의 지속 고용에 달려 있습니다. 이번 부여는 Nasdaq Listing Rule 5635(c)(4)에 따라 이루어졌습니다.
Akebia Therapeutics (Nasdaq : AKBA), une société biopharmaceutique axée sur les traitements des maladies rénales, a accordé des options d’achat d’actions à sept nouveaux employés à titre de primes d’embauche. Les options totalisent 204 163 actions avec un prix d’exercice de 2,73 dollars par action, égal au cours de clôture du 30 septembre 2025. Les options comportent un plan de vesting sur quatre ans avec 25% qui se réalise après un an et les 75% restants vestent trimestriellement par la suite. Chaque option a une durée de 10 ans et est conditionnée à la poursuite de l’emploi chez Akebia. Les attributions ont été effectuées en vertu de la Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Behandlungen von Nierenerkrankungen konzentriert, hat sieben neue Mitarbeiter mit Mitarbeiteraktienoptionen als Anreizprämien geschaffen. Die Optionen belaufen sich auf insgesamt 204.163 Aktien mit einem Ausübungspreis von 2,73 USD pro Aktie, entsprechend dem Schlusskurs vom 30. September 2025. Die Optionen sehen eine Vesting-Periode von vier Jahren vor, wobei nach einem Jahr 25% vesten und die restlichen 75% anschließend vierteljährlich vesten. Jede Option hat eine Laufzeit von 10 Jahren und ist an eine fortlaufende Beschäftigung bei Akebia gebunden. Die Zuteilungen wurden im Rahmen der Nasdaq Listing Rule 5635(c)(4) vorgenommen.
Akebia Therapeutics (ناسداك: AKBA)، شركة أدوية حيوية تركز على علاجات أمراض الكلى، منحت خيارات أسهم لـ سبعة موظفين جدد كجوائز جاذبة للتوظيف. تبلغ إجمالي خيارات الأسهم 204,163 سهماً بسعر ممارسة 2.73 دولاراً للسهم، وهو مطابق لسعر الإغلاق في 30 سبتمبر 2025. تتميز الخيارات بجدول تقاعد لمدة أربع سنوات مع استحقاق 25% بعد سنة واحتمال استحقاق الـ 75% الباقية بشكل ربع سنوي لاحقاً. كل خيار له مدة عشر سنوات ويعتمد على استمرار التوظيف في أكيبييا. جاءت المنح وفقاً لقاعدة الإدراج 5635(c)(4) في ناسداك.
Akebia Therapeutics（纳斯达克股票代码：AKBA），一家专注于肾脏疾病治疗的生物制药公司，已向七名新员工发放股票期权作为就业诱导性奖励。期权总额为204,163 股，行权价为每股 2.73 美元，与 2025 年 9 月 30 日的收盘价一致。期权具有四年归属期，其中一年后归属 25%，其后每季度归属剩余的 75%。每份期权的有效期为 10 年，且以继续在 Akebia 就业为前提。该等授予按照纳斯达克上市规则 5635(c)(4) 进行。
- None.
- None.
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia’s common stock on September 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What stock options did Akebia Therapeutics (AKBA) grant to new employees in September 2025?
What is the vesting schedule for Akebia Therapeutics' (AKBA) September 2025 employee stock options?
What is the exercise price for Akebia Therapeutics' (AKBA) September 2025 inducement grants?
How long is the term of Akebia Therapeutics' (AKBA) September 2025 employee stock options?
